{"classes":[{"categories":[{"measurements":[{"comment":"Not estimable due to the small number of events.","groupId":"OG000","lowerLimit":"13.0","upperLimit":"NA","value":"46.9"},{"comment":"Not estimable due to the small number of events.","groupId":"OG001","lowerLimit":"1.2","upperLimit":"NA","value":"35.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"PFS is defined as the time from the date of the first dose of study treatment to the date of disease progression using the Revised Response Criteria for Malignant Lymphoma (Cheson 2014), or death from any cause, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with an increased risk of tumor lysis syndrome (TLS) enrolled into the open-label Safety Run-in Period received concurrent ibrutinib at 560 mg once daily and venetoclax starting at 20 mg, and gradually ramped up to a target dose of 400 mg once daily over a 5-week period.","id":"OG000","title":"Safety Run-in: Increased TLS Risk at Baseline"},{"description":"Participants with an low risk of TLS enrolled into the open-label Safety Run-in Period received concurrent ibrutinib at 560 mg once daily and venetoclax starting at 20 mg, and gradually ramped up to a target dose of 400 mg once daily over a 5-week period.","id":"OG001","title":"Safety Run-in: Low TLS Risk at Baseline"}],"paramType":"MEDIAN","populationDescription":"All Enrolled Safety Run-in participants","reportingStatus":"POSTED","timeFrame":"For an overall median time on study of 74.78 months","title":"Progression-free Survival (PFS) (Safety Run-in)","type":"SECONDARY","unitOfMeasure":"months"}